Shawver Laura
SEC CIK 1551891 · EDGAR
BoughtSold
Most active insiders at SPRY, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Chakma Justin | Chief Business Off | — | $1.48M |
| 2 | Karas Eric | Chief Commercial Off | — | $250.0K |
| 3 | Dorsey Brian | COO | — | $190.1K |
| 4 | Fitzpatrick Alexander A | CLO | — | $33.5K |
| 5 | Shah Pratik | Dir | — | — |
Shawver Laura made no open-market trades at SPRY in the last 12 months.
Transactions 28
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-04-08 | 2025-04-07 | SPRY | ARS Pharmaceuticals, Inc. | Shawver Laura | Dir | M - OptEx | $4.85 | +50.0K | 260.3K | +24% | +$242.5K |
| D | 2025-04-08 | 2025-04-07 | SPRY | ARS Pharmaceuticals, Inc. | Shawver Laura | Dir | S - Sale+OE | $12.30 | -50.0K | 210.3K | -19% | -$615.0K |
| DM | 2025-03-07 | 2025-03-05+ | SPRY | ARS Pharmaceuticals, Inc. | Shawver Laura | Dir | M - OptEx | $4.85 | +50.0K | 259.9K | +24% | +$242.5K |
| DM | 2025-03-07 | 2025-03-05+ | SPRY | ARS Pharmaceuticals, Inc. | Shawver Laura | Dir | S - Sale+OE | $11.21 | -50.0K | 210.3K | -19% | -$560.4K |
| DM | 2025-02-04 | 2025-02-03 | SPRY | ARS Pharmaceuticals, Inc. | Shawver Laura | Dir | M - OptEx | $4.54 | +50.0K | 219.4K | +30% | +$227.1K |
| D | 2025-02-04 | 2025-02-03 | SPRY | ARS Pharmaceuticals, Inc. | Shawver Laura | Dir | S - Sale+OE | $12.31 | -50.0K | 210.3K | -19% | -$615.5K |
| D | 2025-01-07 | 2025-01-06 | SPRY | ARS Pharmaceuticals, Inc. | Shawver Laura | Dir | M - OptEx | $3.15 | +50.0K | 260.3K | +24% | +$157.5K |
| D | 2025-01-07 | 2025-01-06 | SPRY | ARS Pharmaceuticals, Inc. | Shawver Laura | Dir | S - Sale+OE | $11.10 | -50.0K | 210.3K | -19% | -$555.0K |
| DM | 2024-12-04 | 2024-12-02+ | SPRY | ARS Pharmaceuticals, Inc. | Shawver Laura | Dir | M - OptEx | $2.00 | +200.0K | 298.3K | +203% | +$399.0K |
| DM | 2024-12-04 | 2024-12-02+ | SPRY | ARS Pharmaceuticals, Inc. | Shawver Laura | Dir | S - Sale+OE | $13.44 | -200.0K | 210.3K | -49% | -$2.69M |
| DM | 2023-09-05 | 2023-09-01 | SPRY | ARS Pharmaceuticals, Inc. | Shawver Laura | Dir | M - OptEx | $1.27 | +100.0K | 213.3K | +88% | +$127.0K |
| D | 2023-09-05 | 2023-09-01 | SPRY | ARS Pharmaceuticals, Inc. | Shawver Laura | Dir | S - Sale+OE | $7.71 | -100.0K | 210.3K | -32% | -$771.0K |
| DM | 2023-08-07 | 2023-08-03+ | SPRY | ARS Pharmaceuticals, Inc. | Shawver Laura | Dir | M - OptEx | $1.27 | +45.0K | 236.5K | +24% | +$57.2K |
| DM | 2023-08-07 | 2023-08-03+ | SPRY | ARS Pharmaceuticals, Inc. | Shawver Laura | Dir | S - Sale+OE | $7.03 | -45.0K | 210.3K | -18% | -$316.4K |
| DM | 2023-08-03 | 2023-08-01+ | SPRY | ARS Pharmaceuticals, Inc. | Shawver Laura | Dir | M - OptEx | $1.27 | +55.0K | 229.1K | +32% | +$69.8K |
| DM | 2023-08-03 | 2023-08-01+ | SPRY | ARS Pharmaceuticals, Inc. | Shawver Laura | Dir | S - Sale+OE | $7.12 | -55.0K | 210.3K | -21% | -$391.8K |
| D | 2023-07-07 | 2023-07-07 | SPRY | ARS Pharmaceuticals, Inc. | Shawver Laura | Dir | S - Sale+OE | $6.36 | -8,858 | 210.3K | -4% | -$56.3K |
| D | 2023-07-07 | 2023-07-07 | SPRY | ARS Pharmaceuticals, Inc. | Shawver Laura | Dir | M - OptEx | $1.27 | +8,858 | 219.2K | +4% | +$11.2K |
| DM | 2023-07-06 | 2023-07-03+ | SPRY | ARS Pharmaceuticals, Inc. | Shawver Laura | Dir | M - OptEx | $1.27 | +91.1K | 236.9K | +63% | +$115.8K |
| DM | 2023-07-06 | 2023-07-03+ | SPRY | ARS Pharmaceuticals, Inc. | Shawver Laura | Dir | S - Sale+OE | $6.48 | -91.1K | 210.3K | -30% | -$590.4K |
| DM | 2023-06-02 | 2023-06-01+ | SPRY | ARS Pharmaceuticals, Inc. | Shawver Laura | Dir | S - Sale+OE | $6.84 | -100.0K | 210.3K | -32% | -$684.0K |
| DM | 2023-06-02 | 2023-06-01+ | SPRY | ARS Pharmaceuticals, Inc. | Shawver Laura | Dir | M - OptEx | $1.27 | +100.0K | 237.3K | +73% | +$127.0K |
| 2023-05-26 | 2023-05-24 | RLAY | Relay Therapeutics, Inc. | Shawver Laura | Dir | G - Gift | — | -12.1K | 40.0K | -23% | — | |
| DM | 2023-05-10 | 2022-11-09+ | SPRY | ARS Pharmaceuticals, Inc. | Shawver Laura | Dir | S - Sale+OE | $5.42 | -143.9K | 210.3K | -41% | -$780.6K |
| DM | 2023-05-10 | 2023-05-08+ | SPRY | ARS Pharmaceuticals, Inc. | Shawver Laura | Dir | M - OptEx | $1.27 | +100.0K | 267.4K | +60% | +$127.0K |
| D | 2022-08-09 | 2022-08-05 | SPRY | ARS Pharmaceuticals, Inc. | Shawver Laura | CEO, Dir | M - OptEx | $1.27 | +78.7K | 254.2K | +45% | +$100.0K |
| D | 2022-05-04 | 2022-05-02 | SPRY | ARS Pharmaceuticals, Inc. | Shawver Laura | CEO, Dir | A - Grant | $0.00 | +68.1K | 175.5K | +63% | $0 |
| D | 2022-02-02 | 2022-02-01 | SPRY | ARS Pharmaceuticals, Inc. | Shawver Laura | CEO, Dir | A - Grant | $0.00 | +27.5K | 107.4K | +34% | $0 |
Purchase Sale Sale after option exercise All abbreviations